Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

被引：0
|
作者：
T. Korkmaz
S. Seber
U. Kefeli
E. Sari
M. Canhoroz
B. Oven
E. Yildirim
N. Yasar
D. Aydin
O. Balvan
N. Sener
S. Yuksel
A. Mert
O. Polat
F. Yumuk
O. Kanat
M. Gumus
N. S. Turhal
机构：
[1] Dr. Lutfi Kirdar Kartal Education and Research Hospital,Department of Medical Oncology
[2] Marmara University Hospital,Medical Oncology Department
[3] Uludag University Hospital,Medical Oncology Department
[4] Marmara University Hospital,Internal Medicine Department
来源：
Clinical and Translational Oncology | 2013年 / 15卷
关键词：
Platinum sensitive disease; Platinum refracter disease; Second-line chemotherapy; Small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：535 / 540
页数：5
相关论文
共 50 条
  • [41] Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer
    Azkona, E.
    Carrera, S.
    Rubio, I.
    Mane, J. M.
    Lacambra, I.
    Sancho, A.
    Novo, E.
    Lopez-Vivanco, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S969 - S969
  • [42] Epirubicin plus Paclitaxel Regimen as Second-line Treatment of Patients with Small-cell Lung Cancer
    Pasello, Giulia
    Carli, Paolo
    Canova, Fabio
    Bonanno, Laura
    Polo, Valentina
    Zago, Giulia
    Urso, Loredana
    Conte, Pierfranco
    Favaretto, Adolfo
    ANTICANCER RESEARCH, 2015, 35 (04) : 2183 - 2189
  • [43] Retrospective review of paditaxel beyond second-line therapy in patients with small cell cancer
    Kalwar, Tricia L.
    Raftopoulos, Haralambos
    Paul, Doru
    Devoe, Craig E.
    Kohn, Nina
    Fields, Scott Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
    Hanvesakul, Raj
    Rengarajan, Badri
    Naveh, Navit
    Boccuti, Anne
    Park, Julie E.
    Adeyemi, Adekemi
    Caisip, Clyde
    Jansen, Jeroen P.
    Wilson, Florence R.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (05)
  • [45] Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
    Reck, Martin
    Garassino, Marina Chiara
    Imbimbo, Martina
    Shepherd, Frances A.
    Socinski, Mark A.
    Shih, Jin-Yuan
    Tsao, Anne
    Lee, Pablo
    Winfree, Katherine B.
    Sashegyi, Andreas
    Cheng, Rebecca
    Varea, Rocio
    Levy, Benjamin
    Garon, Edward
    LUNG CANCER, 2018, 120 : 62 - 69
  • [46] Current status of second-line treatment and novel therapies for small cell lung cancer
    Tiseo, Marcello
    Ardizzoni, Andrea
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 764 - 772
  • [47] Single agents in the second-line treatment of non-small cell lung cancer
    Belani, CP
    SEMINARS IN ONCOLOGY, 1998, 25 (03) : 10 - 14
  • [48] Second-line treatment options in advanced non-small cell lung cancer
    de Marinis, Filippo
    Ricciardi, Serena
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S258 - S271
  • [49] An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
    Patel, Shetal
    Petty, William Jeffrey
    Sands, Jacob M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [50] Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
    Xu, Jianlin
    Zhang, Xueyan
    Yang, Haitang
    Ding, Guozheng
    Jin, Bo
    Lou, Yuqing
    Zhang, Yanwei
    Wang, Huimin
    Han, Baohui
    ONCOTARGET, 2016, 7 (42) : 68442 - 68448
12345